These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 28460827)

  • 1. Heart failure.
    Metra M; Teerlink JR
    Lancet; 2017 Oct; 390(10106):1981-1995. PubMed ID: 28460827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-treatment mismatch in the pharmacotherapy of heart failure.
    Lee DS; Tu JV; Juurlink DN; Alter DA; Ko DT; Austin PC; Chong A; Stukel TA; Levy D; Laupacis A
    JAMA; 2005 Sep; 294(10):1240-7. PubMed ID: 16160132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring new treatment strategies in heart failure.
    Swedberg K
    Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China.
    Liu X; Yu H; Pei J; Chu J; Pu J; Zhang S
    Heart Lung Circ; 2014 Sep; 23(9):818-26. PubMed ID: 24881031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
    Shah R; Wang Y; Foody JM
    Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.
    Voors AA; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Ter Maaten JM; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; Metra M
    Eur J Heart Fail; 2016 Jun; 18(6):716-26. PubMed ID: 27126231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac contractility modulation: a novel approach for the treatment of heart failure.
    Abi-Samra F; Gutterman D
    Heart Fail Rev; 2016 Nov; 21(6):645-660. PubMed ID: 27394714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS.
    Khazanie P; Hammill BG; Patel CB; Kiernan MS; Cooper LB; Arnold SV; Fendler TJ; Spertus JA; Curtis LH; Hernandez AF
    J Card Fail; 2016 Sep; 22(9):672-9. PubMed ID: 26892975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
    Krantz MJ; Ambardekar AV; Kaltenbach L; Hernandez AF; Heidenreich PA; Fonarow GC;
    Am J Cardiol; 2011 Jun; 107(12):1818-23. PubMed ID: 21482418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials of beta-blockers in heart failure: a class review.
    Yancy CW
    Am J Med; 2001 Apr; 110 Suppl 5A():7S-10S. PubMed ID: 11259751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.